VIE:EURONEXT PARISVeolia Environnement SA Analysis
Data as of 2026-07-20 - not real-time
$0.00
Latest Price
9/10Risk
Risk Level: High
Executive Summary
ViewRay Systems (VIE) is trading at $0.0001 with a market cap of roughly $18 k, reflecting extreme distress. The company filed for Chapter 7 liquidation in late 2023, indicating that its assets are being sold to satisfy creditors. Financials show revenue of $105.9 M with 19.4% growth, yet gross margin is only 8%, operating margin –131%, and net profit margin –104%, highlighting unsustainable operations. EBITDA is a negative $102.7 M and both operating and free cash flow are deeply negative, confirming cash burn. The balance sheet reveals $85.1 M of debt versus $81.3 M of cash, resulting in a debt‑to‑equity ratio above 150% and negative ROE. Technical indicators are neutral on trend, but RSI is at the maximum 100 and MACD histogram is bearish, suggesting no buying pressure.
The beta of –21 (computed) and zero 30‑day volatility underscore that price movements are random noise rather than market‑driven signals. Liquidity is virtually nonexistent, with daily volume of only 3 k shares and an average volume of zero, making any trade highly risky. The Fear & Greed Index reads “Extreme Greed,” but this is meaningless for a company in liquidation. With no dividend, no analyst coverage, and a PE ratio that is effectively zero, valuation metrics cannot be applied meaningfully. Given the bankruptcy status and negative cash generation, the stock is effectively a speculative claim on residual assets rather than an investment. Consequently, the prudent stance is to avoid exposure across all horizons.
The beta of –21 (computed) and zero 30‑day volatility underscore that price movements are random noise rather than market‑driven signals. Liquidity is virtually nonexistent, with daily volume of only 3 k shares and an average volume of zero, making any trade highly risky. The Fear & Greed Index reads “Extreme Greed,” but this is meaningless for a company in liquidation. With no dividend, no analyst coverage, and a PE ratio that is effectively zero, valuation metrics cannot be applied meaningfully. Given the bankruptcy status and negative cash generation, the stock is effectively a speculative claim on residual assets rather than an investment. Consequently, the prudent stance is to avoid exposure across all horizons.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 9/10
Key Factors
- Chapter 7 liquidation
- Negative cash flow and margins
- Illiquid market price
Medium Term
1–3 yearsCautious
Model confidence: 7/10
Key Factors
- No viable operating model
- High debt load
- Regulatory and bankruptcy uncertainty
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Residual asset liquidation risk
- Continued negative earnings
- Lack of cash generation
Key Metrics & Analysis
Financial Health
Revenue Growth19.40%
Profit Margin-104.30%
P/E Ratio-0.0
ROE-108.91%
ROA-25.29%
Debt/Equity154.07
P/B Ratio0.0
Op. Cash Flow$-112922000
Free Cash Flow$-72168376
Industry P/E29.0
Technical Analysis
TrendNeutral
RSI100.0
Support$0.00
Resistance$0.00
MA 20$0.00
MA 50$0.00
MA 200$0.00
MACDBearish
VolumeStable
Fear & Greed Index87.91
Valuation
GradeFair
TypeBlend
Risk Assessment
Beta-11.97
0Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.